Lung Cancer Drug Cuts Recurrence Risk by 83%

A targeted therapy called selpercatinib dramatically reduces the chance of early-stage lung cancer returning in patients with a rare genetic subtype.

After two years, 92% of patients who received the drug remained cancer-free compared to just 61% who got a placebo.